Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA2D1 known ✓ | P54289 | 2/20 | 0.48 |
| ▸ | CACNB3 known ✓ | P54284 | 1/20 | 0.48 |
| ▸ | CACNA1C known ✓ | Q13936 | 1/20 | 0.48 |
| ▸ | ADRA1A known ✓ | P35348 | 1/20 | 0.48 |
| ▸ | HTR2B known ✓ | P41595 | 1/20 | 0.48 |
| ▸ | CACNA2D2 known ✓ | Q9NY47 | 1/20 | 0.48 |
| ▸ | GABRP known ✓ | O00591 | 2/20 | 0.35 |
| ▸ | GABRD known ✓ | O14764 | 2/20 | 0.35 |
| ▸ | GABRA1 known ✓ | P14867 | 2/20 | 0.35 |
| ▸ | GABRB1 known ✓ | P18505 | 2/20 | 0.35 |
| ▸ | GABRG2 known ✓ | P18507 | 2/20 | 0.35 |
| ▸ | GABRB3 known ✓ | P28472 | 2/20 | 0.35 |
| ▸ | GABRA5 known ✓ | P31644 | 2/20 | 0.35 |
| ▸ | GABRA3 known ✓ | P34903 | 2/20 | 0.35 |
| ▸ | GABRA2 known ✓ | P47869 | 2/20 | 0.35 |
| ▸ | GABRB2 known ✓ | P47870 | 2/20 | 0.35 |
| ▸ | GABRA4 known ✓ | P48169 | 2/20 | 0.35 |
| ▸ | GABRE known ✓ | P78334 | 2/20 | 0.35 |
| ▸ | GABRA6 known ✓ | Q16445 | 2/20 | 0.35 |
| ▸ | GABRG1 known ✓ | Q8N1C3 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL7747512 | 0.98 | CACNA2D1 (0.47) | CACNA2D1CACNB3CACNA1CPGRADRA1A | |
| SCHEMBL9866878 | 0.98 | CACNA2D1 (0.50) | CACNA2D1CACNB3CACNA1CPGRADRA1A | |
| SCHEMBL29409291 | 0.98 | CACNA2D1 (0.50) | CACNA2D1CACNB3CACNA1CPGRADRA1A | |
| SCHEMBL9819784 | 0.98 | CACNA2D1 (0.50) | CACNA2D1CACNB3CACNA1CPGRADRA1A | |
| SCHEMBL8594 | 0.98 | CACNA2D1 (0.50) | CACNA2D1CACNB3CACNA1CPGRADRA1A | |
| SCHEMBL8492066 | 0.98 | CACNA2D1 (0.50) | CACNA2D1CACNB3CACNA1CPGRADRA1A | |
| SCHEMBL42411 | 0.98 | CACNA2D1 (0.50) | CACNA2D1CACNB3CACNA1CPGRADRA1A | |
| SCHEMBL27594545 | 0.98 | CACNA2D1 (0.50) | CACNA2D1CACNB3CACNA1CPGRADRA1A | |
| SCHEMBL8530515 | 0.98 | CACNA2D1 (0.50) | CACNA2D1CACNB3CACNA1CPGRADRA1A | |
| SCHEMBL2746636 | 0.98 | CACNA2D1 (0.50) | CACNA2D1CACNB3CACNA1CPGRADRA1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 303 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116836131-A | Synthesis of 1- (2- (1, 1-diphenylethoxy) ethyl) azepane | 回音必集团抚州制药有限公司 | 2023-10-03 | — | — | CN | claimed |
| CN-108998417-A | Multipotential stem cell inducer and its application | 广州医大新药创制有限公司 | 2018-12-14 | — | — | CN | claimed |
| US-12440444-B2 | Matrix bound vesicles (MBVS) containing IL-33 and their use | University of Pittsburgh—of the Commonwealth System of Higher Education (US) | 2025-10-14 | — | — | US | disclosed |
| US-20240377399-A1 | COMPOSITIONS AND METHODS FOR MODULATING HYDROXYLATION OF ACC2 BY PHD3 | PRESIDENT AND FELLOWS OF HARVARD COLLEGE | 2024-11-14 | — | — | US | disclosed |
| US-20240190837-A1 | CARBAZOLE-CONTAINING AMIDES, CARBAMATES, AND UREAS AS CRYPTOCHROME MODULATORS | SYCHRONICITY PHARMA INC (US) | 2024-06-13 | — | — | US | disclosed |
| CN-117342993-A | Trafarotene salt, pharmaceutical composition and application thereof | 石家庄迪斯凯威医药科技有限公司 | 2024-01-05 | — | — | CN | disclosed |
| CN-117304004-A | Preparation process of grignard alcohol | 江西东抚制药有限公司 | 2023-12-29 | — | — | CN | disclosed |
| CN-116836131-A | Synthesis of 1- (2- (1, 1-diphenylethoxy) ethyl) azepane | 回音必集团抚州制药有限公司 | 2023-10-03 | — | — | CN | disclosed |
| CN-116836131-A | Synthesis of 1- (2- (1, 1-diphenylethoxy) ethyl) azepane | 回音必集团抚州制药有限公司 | 2023-10-03 | — | — | CN | disclosed |
| US-20220411399-A1 | CARBAZOLE-CONTAINING AMIDES, CARBAMATES, AND UREAS AS CRYPTOCHROME MODULATORS | SYCHRONICITY PHARMA INC (US) | 2022-12-29 | — | — | US | disclosed |
| CN-115340538-A | 8-phenyliminomethyl berberine type derivatives and application thereof in preparing medicines | 中国医学科学院药物研究所 | 2022-11-15 | — | — | CN | disclosed |
| WO-1998046224-A1 | COMPOSITIONS AND METHOD FOR TREATING BLADDER DYSFUNCTION | BRIGHAM & WOMEN'S HOSPITAL, INC. (US) | 1998-10-22 | — | — | WO | disclosed |
| WO-1998039354-A1 | FAS LIGAND COMPOSITIONS FOR TREATMENT OF PROLIFERATIVE DISORDERS | ST. ELIZABETH'S MEDICAL CENTER OF BOSTON, INC. (US) | 1998-09-11 | — | — | WO | disclosed |
| EP-0859611-A1 | ENHANCEMENT OF ERECTILE FUNCTION WITH RENIN-ANGIOTENSIN SYSTEM INHIBITORS | BRIGHAM & WOMEN'S HOSPITAL, INC. (US) | 1998-08-26 | — | — | EP | disclosed |
| WO-1998010090-A1 | GATA-6 TRANSCRIPTION FACTOR: COMPOSITIONS AND METHODS | ST. ELIZABETH'S MEDICAL CENTER OF BOSTON, INC. (US) | 1998-03-12 | — | — | WO | disclosed |
| US-5658936-A | ADMINISTERING DOSE OF RENIN-ANGIOTENSIN SYSTEM INHIBITOR WHICH MODIFIES ACUTELY SYSTEMIC BLOOD PRESSURE BY LESS THAN TEN PERCENT | BRIGHAM & WOMEN'S HOSPITAL, INC. (US) | 1997-08-19 | — | — | US | disclosed |
| WO-1997010821-A1 | ENHANCEMENT OF ERECTILE FUNCTION WITH RENIN-ANGIOTENSIN SYSTEM INHIBITORS | BRIGHAM & WOMEN'S HOSPITAL, INC. (US) | 1997-03-27 | — | — | WO | disclosed |
| EP-0641218-A1 | USE OF RENIN-ANGIOTENSIN ANTAGONIST FOR REDUCING POST MYOCARDIAL INFARCT MOBIDITY AND MORTALITY | BRIGHAM AND WOMEN'S HOSPITAL (US) | 1995-03-08 | — | — | EP | disclosed |
| WO-1993020839-A2 | USE OF RENIN-ANGIOTENSIN ANTAGONIST FOR REDUCING POST MYOCARDIAL INFARCT MOBIDITY AND MORTALITY | BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 1993-10-28 | — | — | WO | disclosed |
| US-5066643-A | Enzyme inhibitors, protease and esterase, hypotensive agents, congestive heart failure | SANDOZ LTD. (CH) | 1991-11-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220411399-A1 | CARBAZOLE-CONTAINING AMIDES, CARBAMATES, AND UREAS AS CRYPTOCHROME MODULATORS | CRY1, CRY2, HCCS | CACNA2D1 3428/4885CACNB3 4141/4885CACNA1C 4149/4885 |
| US-20240190837-A1 | CARBAZOLE-CONTAINING AMIDES, CARBAMATES, AND UREAS AS CRYPTOCHROME MODULATORS | CRY1, CRY2, HCCS | CACNA2D1 3428/4885CACNB3 4141/4885CACNA1C 4149/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.